High Plasma Levels of Soluble Lectin‐like Oxidized Low‐Density Lipoprotein Receptor‐1 Are Associated With Inflammation and Cardiometabolic Risk Profiles in Pediatric Overweight and Obesity
Journal of the American Heart Association, 2023
Stinson S., Jonsson A., Andersen M., Lund M., Holm L., Fonvig C., Huang Y., Stankevič E., Juel H., Ängquist L., Sørensen T., Ongstad E., Gaddipati R., Grimsby J., Rhodes C., Pedersen O., Christiansen M., Holm J., Hansen T.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Metabolic Diseases CVD | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
Background
Lectin‐like oxidized low‐density lipoprotein (ox‐LDL) receptor‐1 is a scavenger receptor for oxidized low‐density lipoprotein. In adults, higher soluble lectin‐like ox‐LDL receptor‐1 (sLOX‐1) levels are associated with cardiovascular disease, type 2 diabetes, and obesity, but a similar link in pediatric overweight/obesity remains uncertain.
Methods and Results
Analyses were based on the cross‐sectional HOLBAEK Study, including 4‐ to 19‐year‐olds from an obesity clinic group with body mass index >90th percentile (n=1815) and from a population‐based group (n=2039). Fasting plasma levels of sLOX‐1 and inflammatory markers were quantified, cardiometabolic risk profiles were assessed, and linear and logistic regression analyses were performed. Pubertal/postpubertal children and adolescents from the obesity clinic group exhibited higher sLOX‐1 levels compared with the population ( P <0.001). sLOX‐1 positively associated with proinflammatory cytokines, matrix metalloproteinases, body mass index SD score, waist SD score, body fat %, plasma alanine aminotransferase, serum high‐sensitivity C‐reactive protein, plasma low‐density lipoprotein cholesterol, triglycerides, systolic and diastolic blood pressure SD score, and inversely associated with plasma high‐density lipoprotein cholesterol (all P <0.05). sLOX‐1 positively associated with high alanine aminotransferase (odds ratio [OR], 1.16, P =4.1 E‐04), insulin resistance (OR, 1.16, P =8.6 E‐04), dyslipidemia (OR, 1.25, P =1.8 E‐07), and hypertension (OR, 1.12, P =0.02).
Conclusions
sLOX‐1 levels were elevated during and after puberty in children and adolescents with overweight/obesity compared with population‐based peers and associated with inflammatory markers and worsened cardiometabolic risk profiles. sLOX‐1 may serve as an early marker of cardiometabolic risk and inflammation in pediatric overweight/obesity.
Registration
The HOLBAEK Study, formerly known as The Danish Childhood Obesity Biobank, ClinicalTrials.gov identifier number NCT00928473, https://clinicaltrials.gov/ct2/show/NCT00928473 (registered June 2009).